By Kieran Killough, partner, HGF Limited
For many years, medical device companies operated in a regulatory environment where significant product and compliance information was held within national systems and was therefore difficult for competitors to access.
The European Database on Medical Devices (EUDAMED) changes that landscape.
Developed under the EU Medical Device Regulation (MDR) and In Vitro Diagnostic Medical Devices Regulation (IVDR), EUDAMED provides a comprehensive, centralised platform for information on medical devices marketed in the European Union.
While the regulatory benefits of EUDAMED are clear, including improved transparency, traceability and patient safety, the system also presents IP challenges that medtech companies should not underestimate.
From an IP lawyer’s perspective, EUDAMED is not simply a compliance tool. It is also a source of valuable information for competitors, investors, litigants and other market participants.
Companies should therefore align regulatory compliance and IP protection strategies.
What is EUDAMED?
EUDAMED is the European Commission’s central database for medical devices and in vitro diagnostic devices. It is designed to create a single source of information regarding the lifecycle of medical devices within the EU market.
The system consists of six modules covering:
- Actor registration;
- Unique Device Identifier (UDI) and device registration;
- Notified bodies and certificates;
- Clinical investigations and performance studies;
- Vigilance and post-market surveillance; and
- Market surveillance.
Following a phased rollout, four modules have now reached mandatory implementation stages: actor registration, UDI and device registration, notified bodies and certificates, and market surveillance.
The remaining modules, covering clinical investigations and performance studies, and vigilance and post-market surveillance, are expected to become mandatory later.
EUDAMED aims to improve transparency, coordination between competent authorities, market oversight and information for healthcare professionals and patients.
However, any transparency that benefits regulators and patients may also benefit competitors.
Why EUDAMED Raises IP Concerns
Unlike patents, which provide protection in exchange for public disclosure, trade secrets derive their value precisely because they are not publicly known.
Many medical device companies rely heavily on confidential know-how, manufacturing processes, software architecture, clinical strategies and product development plans that may not be fully captured by registered IP rights.
The principal IP risk associated with EUDAMED is therefore not the loss of patent rights per se, but the gradual erosion of confidentiality through mandatory disclosure.
While EUDAMED does not require publication of complete technical documentation, it does require a significant amount of structured information on devices and regulatory status.
When viewed in isolation, individual data points may appear innocuous. Collectively, however, they can create a detailed picture of a company’s product portfolio and strategic direction.
Competitors are becoming increasingly sophisticated in analysing publicly available data.
Information that once required extensive and expensive market research can now be obtained by monitoring regulatory databases, and powerful AI tools make extracting insights easier.
Trade Secret and Know-How Risks
One of the most significant concerns is the potential exposure of trade secrets and commercially sensitive know-how.
For example, device descriptions, intended use statements, Basic UDI-DI structures and product family information may reveal more than companies realise.
Sophisticated competitors can use this information to infer product architecture, technology platforms, development pathways and commercial strategy.
This issue is particularly relevant for software-driven medical devices and digital health technologies, where competitive advantage often lies not in a single patent but in a combination of proprietary algorithms, system architecture and accumulated expertise.
Even where direct disclosure is avoided, EUDAMED can enable competitors to combine multiple data points to generate insights that would previously have remained confidential.
Enhanced Competitive Intelligence
Historically, obtaining information about a competitor’s regulatory activities could be both time-consuming and expensive. EUDAMED substantially lowers these barriers.
The database makes it easier to identify:
- New products entering the market;
- Changes to device portfolios;
- Certificate renewals and expirations;
- Product withdrawals;
- Corporate relationships; and
- Regulatory positioning.
Commercially, this transparency can be valuable. From an IP perspective, it creates competitive pressure by allowing competitors to monitor innovation activity more effectively.
A competitor that knows when a new product family is approaching market entry may accelerate competing developments, adjust pricing strategies, prepare freedom-to-operate analyses or strengthen its own patent portfolio in anticipation of market changes.
Competitors might also use the database to confirm any suspected infringements of their own patents.
Clinical Data and Future Disclosure Risks
Additional considerations will arise as the remaining EUDAMED modules become operational.
The clinical investigations and vigilance modules are expected to increase available information on device performance, safety and post-market experience.
Certain higher-risk devices also require publication of a Summary of Safety and Clinical Performance (SSCP).
Although these transparency measures serve important public health objectives, they may also provide competitors with valuable intelligence regarding:
- Clinical endpoints;
- Study designs;
- Performance characteristics;
- Benefit-risk assessments; and
- Product differentiation strategies.
For innovative companies that have invested heavily in generating clinical evidence, these disclosures may give competitors access to insights that required significant investment to obtain.
Patent Strategy Considerations
Patent protection and regulatory disclosure are often managed as separate disciplines within organisations. EUDAMED makes this separation increasingly difficult to justify.
A key consideration is ensuring that patent filing strategies are aligned with regulatory disclosure activities.
Innovative product features, new indications, software functionalities or novel device configurations should ideally be protected through patent filings before details become publicly accessible.
While EUDAMED disclosures will not necessarily destroy patentability in every jurisdiction, premature disclosure can complicate patent prosecution, create prior art issues and reduce flexibility when developing future filing strategies.
For this reason, regulatory teams should work closely with internal and external patent counsel when preparing submissions that contain information relating to ongoing innovation programmes.
Best Practice for Risk Mitigation
Fortunately, the risks associated with EUDAMED can be managed through careful planning and governance.
- Involve IP Counsel Early
Regulatory submissions should be reviewed not only by regulatory affairs specialists but also by legal and IP professionals where appropriate.
This is particularly important for:
- Device descriptions;
- Intended purpose statements;
- Clinical summaries;
- Product family structures; and
- Public-facing disclosures.
An IP review can identify opportunities to reduce unnecessary disclosure while still satisfying regulatory requirements.
- Apply the Principle of Data Minimisation
Companies should disclose what is required by law and no more.
This does not mean withholding mandatory information. Rather, it means avoiding unnecessary technical detail, strategic commentary or marketing language that may reveal valuable information to competitors.
Particular care should be taken when drafting narrative or free-text sections.
- Integrate Patent and Regulatory Planning
Regulatory disclosure milestones should be incorporated into patent portfolio management processes.
Before significant EUDAMED submissions are made, companies should ask:
- Have relevant patent applications been filed?
- Does the disclosure reveal potentially patentable subject matter?
- Could competitors gain an advantage from this information?
Answering these questions early can prevent costly mistakes later.
- Establish Internal Governance
Many organisations would benefit from a formal EUDAMED disclosure policy.
Such a policy should define:
- Approval processes;
- Responsibility for review;
- Escalation procedures;
- Confidentiality assessments; and
- Record-keeping requirements.
Training regulatory personnel on IP risks is equally important, as many disclosures are prepared by teams whose primary focus is compliance rather than IP protection.
- Use EUDAMED as a Strategic Intelligence Tool
Finally, companies should recognise that EUDAMED operates in both directions. If competitors can monitor your activities, you can monitor theirs.
Regular review of competitor registrations, certifications and product developments can support:
- Competitive intelligence programmes;
- Patent landscaping exercises;
- Validity attacks of competitor IP;
- Freedom-to-operate assessments; and
- Strategic business planning.
Conclusion
EUDAMED represents one of the most significant transparency initiatives introduced under the MDR and IVDR frameworks.
Whilst its regulatory objectives are entirely understandable, the database also changes the way commercially sensitive information is exposed and analysed within the medical technology sector.
For medtech companies, the greatest risk is not necessarily the loss of formal IP rights, but the gradual disclosure of information that enables competitors to understand product pipelines, innovation strategies and market positioning.
Information that may appear relatively benign in isolation, such as device descriptions, intended use statements, Basic UDI-DI structures or clinical information, can collectively provide valuable insights into a company’s technology platforms and commercial priorities.
The organisations best placed to succeed in this new environment will be those that take a proactive and coordinated approach to managing regulatory disclosures.
Regulatory compliance, intellectual property strategy and commercial objectives can no longer be considered in isolation.
Companies should ensure that EUDAMED submissions are reviewed through both a regulatory and IP lens, that patent filing strategies are aligned with disclosure obligations, and that appropriate governance processes are in place to protect valuable know-how and confidential information.
As transparency requirements continue to increase, navigating the intersection between regulatory compliance and intellectual property protection is becoming more complex.
HGF has extensive experience advising medtech businesses on patent strategy, trade secrets, regulatory-related IP issues and freedom-to-operate considerations.
By combining technical, legal and commercial expertise, we help clients protect and maximise the value of their innovation while mitigating the risks associated with an increasingly transparent regulatory environment.
Find out more about HGF at hgf.com
